Ergoteles LLC Gossamer Bio, Inc. Transaction History

Ergoteles LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.53 $1.68 Million - $2.62 Million	-1,710,324 Reduced 98.75%	21,600 $25,000
Q1 2023 May 10, 2023	BUY	$0.96 - $2.92 $1.66 Million - $5.06 Million	1,731,924 New	1,731,924 $2.18 Million
Q1 2022 May 13, 2022	SELL	$8.44 - $12.49 $340,267 - $503,546	-40,316 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.12 - $14.07 $20,412 - $28,379	-2,017 Reduced 4.76%	40,316 $456,000
Q3 2021 Nov 15, 2021	BUY	$7.25 - $13.23 $306,914 - $560,065	42,333 New	42,333 $532,000

108

167M

430K

519K

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $93M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.